Holen Sie sich die Stockscreener-App
3.975
3.99%
-0.165
Curevac N V Aktie (CVAC) Neueste Nachrichten
CureVac (NASDAQ:CVAC) Stock Price Down 3.7%What's Next? - MarketBeat
CureVac (NASDAQ:CVAC) Shares Up 4.7%Should You Buy? - MarketBeat
Jane Street Group LLC Has $235,000 Stock Position in CureVac (NASDAQ:CVAC) - Defense World
Geode Capital Management LLC Lowers Position in CureVac (NASDAQ:CVAC) - Defense World
CureVac NV (FRA:5CV) 50-Day SMA : €2.91 (As of Jan. 11, 2025) - GuruFocus.com
CVAC (CureVac NV) 14-Day RSI : 68.17 (As of Jan. 10, 2025) - GuruFocus.com
CureVac (NASDAQ:CVAC) Trading 5.7% HigherHere's What Happened - MarketBeat
Why CureVac (CVAC) Shares Are Volatile - Benzinga
CureVac: Latest GBM Data Bodes Well For Next Program Check Point (NASDAQ:CVAC) - Seeking Alpha
Why CureVac (CVAC) Stock Is Moving - Benzinga
CureVac (NASDAQ:CVAC) Shares Gap DownHere's What Happened - MarketBeat
CureVac (NASDAQ:CVAC) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
CureVac (NASDAQ:CVAC) Shares Gap UpHere's Why - MarketBeat
Why CureVac (CVAC) Stock Is Rising - Benzinga
Subdued Growth No Barrier To CureVac N.V. (NASDAQ:CVAC) With Shares Advancing 25% - Simply Wall St
Short Interest in CureVac (NASDAQ:CVAC) Declines By 6.4% - MarketBeat
CureVac (NASDAQ:CVAC) Trading Up 3.6% – Still a Buy? - Defense World
CureVac (NASDAQ:CVAC) Stock Quotes, Forecast and News Summary - Benzinga
CureVac (NASDAQ:CVAC) Stock Price Up 3.6%Here's What Happened - MarketBeat
CureVac (NASDAQ:CVAC) Trading Up 4.7%What's Next? - MarketBeat
CureVac (NASDAQ:CVAC) Shares Down 5.5%What's Next? - MarketBeat
CureVac's SWOT analysis: mRNA pioneer's stock faces oncology pipeline hurdles - Investing.com
2 Small-Cap Stocks Set to Shine in a Bull Market - Benzinga
CUREVAC : Licensing deal boosts bank account - Marketscreener.com
Point72 Asset Management L.P. Sells 1,642,723 Shares of CureVac (NASDAQ:CVAC) - MarketBeat
CUREVAC : Positive one-off overshadows pipeline dryness - Marketscreener.com
mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider - GlobeNewswire Inc.
CureVac NV (XTER:5CV) 50-Day SMA : €2.62 (As of Dec. 05, 2024) - GuruFocus.com
CureVac NV (STU:5CV) 5-Day RSI : 64.31 (As of Dec. 05, 2024) - GuruFocus.com
CureVac's SWOT analysis: mRNA pioneer's stock faces pivotal phase in oncology push - Investing.com
CureVac NV (LTS:0A9E) EBITDA per Share : $0.84 (TTM As of Sep. 2024) - GuruFocus.com
CureVac NV (LTS:0A9E) Profitability Rank : 3 (As of Sep. 2024) - GuruFocus.com
CureVac NV (LTS:0A9E) 3-Year FCF Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
CureVac NV (HAM:5CV) Cyclically Adjusted FCF per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
CureVac NV (WBO:CVAC) Enterprise Value : €94.9 Mil (As of Dec. 01, 2024) - GuruFocus.com
CureVac NV (HAM:5CV) Altman Z-Score : 2.46 (As of Dec. 01, 2024) - GuruFocus.com
CureVac NV (STU:5CV) 3-Year FCF Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
CureVac NV (STU:5CV) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
CVAC (CureVac NV) 9-Day RSI : 62.66 (As of Nov. 30, 2024) - GuruFocus.com
CVACCureVac N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC) - Simply Wall St
CureVac NV (STU:5CV) Total Assets : €854.2 Mil (As of Sep. 2024) - GuruFocus.com
CVAC (CureVac NV) Capex-to-Operating-Cash-Flow : 0.01 (As of Sep. 2024) - GuruFocus.com
Loss-Making CureVac N.V. (NASDAQ:CVAC) Set To Breakeven - Yahoo Finance
Is the Options Market Predicting a Spike in CureVac (CVAC) Stock? - MSN
CureVac NV (STU:5CV) Total Inventories : €0.5 Mil (As of Sep. 2024) - GuruFocus.com
CureVac NV (STU:5CV) 50-Day SMA : €2.65 (As of Nov. 21, 2024) - GuruFocus.com
CureVac NV (XTER:5CV) Float Percentage Of Total Shares Outs - GuruFocus.com
CureVac NV (STU:5CV) Retained Earnings : €-1,371.0 Mil (As of Sep. 2024) - GuruFocus.com
CureVac NV (FRA:5CV) Retained Earnings : €-1,371.0 Mil (As of Sep. 2024) - GuruFocus.com
CureVac NV (FRA:5CV) Free Cash Flow : €94.5 Mil (TTM As of Sep. 2024) - GuruFocus.com
CureVac NV (HAM:5CV) 3-Year Revenue Growth Rate : -16.20% (As of Sep. 2024) - GuruFocus.com
CureVac NV (FRA:5CV) EBITDA : €165.9 Mil (TTM As of Sep. 2024) - GuruFocus.com
CureVac’s stock soars on GSK’s $1.56 billion deal for its COVID-19 and flu vaccines - MSN
10 Best German Stocks To Buy Now - Insider Monkey
1.43%
7.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):